TLDR The treatment was ineffective in humans.
The study investigated the efficacy of CUR61414, a topical inhibitor of the Hedgehog signaling molecule Smoothened, in treating basal cell carcinomas (BCC). Preclinical tests on mice showed that CUR61414 significantly inhibited Hedgehog signaling, blocked hair follicle growth, and reduced BCC size. However, in a phase I clinical trial involving human subjects with superficial or nodular BCCs, the treatment showed no clinical activity. The results underscore the difficulties in translating successful preclinical findings into effective human treatments.
63 citations,
May 2011 in “Clinical cancer research” The topical inhibitor CUR61414 was not effective in treating basal cell carcinoma in human trials.
15 citations,
October 2014 in “Journal of Investigative Dermatology” New treatments targeting the Hedgehog pathway can help treat advanced skin cancer but may have side effects and their effectiveness in early stages is unknown.
[object Object] 
36 citations,
September 2009 in “Journal of Cellular and Molecular Medicine” New treatments targeting skin stem cells show promise for skin repair, anti-aging, and cancer therapy.
1 citations,
November 2002 in “Journal of dermatology” The antibody created from BCC tissues reacts similarly to both BCC and hair follicles, suggesting BCC may come from hair follicle cells.
351 citations,
February 2010 in “Nature Cell Biology” Basal cell carcinoma mostly starts from cells in the upper skin layers, not hair follicle stem cells.
